Alar Pharmaceuticals Inc. (TPEX: 6785)

Market Cap	12.22B
Revenue (ttm)	469.27M
Net Income (ttm)	417.67M
Shares Out	66.80M
EPS (ttm)	6.81
PE Ratio	26.86
Forward PE	234.62
Dividend	1.50 (0.79%)
Ex-Dividend Date	Jun 5, 2024

Volume	211,584
Open	192.50
Previous Close	191.00
Day's Range	181.00 - 194.00
52-Week Range	138.50 - 465.00
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founde...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 22
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6785